About
ATLATL is a life-science innovation and shared-lab operator founded in 2017 in Shanghai's Zhangjiang, providing move-in-ready labs, on-site CRO services and R&D platforms (gene and cell therapy, AI-assisted drug screening, large-molecule research) to early-stage biotech companies across Shanghai, Beijing, Shenzhen, Hong Kong, Singapore and Australia.
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- ATLATL Innovation Center
ATLATL is a life-science innovation and shared-lab operator founded in 2017 in Shanghai's Zhangjiang, providing move-in-ready labs, on-site CRO services and R&D platforms (gene and cell therapy, AI-assisted drug screening, large-molecule research) to early-stage biotech companies across Shanghai, Beijing, Shenzhen, Hong Kong, Singapore and Australia.
—
United States
BusinessLatest roundTotal raisedDate- Optagon
AI digital twin system for drug developers that jointly optimizes multiple drug properties and plans next experiments in preclinical stages such as lead optimization and candidate selection
— - Onepot
Small-molecule synthesis for drug discovery for biopharma companies (AI + automated synthesis)
Seed · $13M · 2025-11
$13M - DeepSeq.AI
DeepSeq.AI, founded in 2019 and based in California, is an AI protein drug discovery company that combines high-throughput wet-lab assays with protein language models and generative AI to predict and optimize biologics properties (affinity, specificity, immunogenicity, PK, manufacturability) for large biopharma partners. It has DARPA and NSF funding, accelerator backing from Merck Digital Sciences Studio, StartX and SkyDeck, and investment from Illumina Ventures and Zaka VC.
$620K
$620K
China
BusinessLatest roundTotal raisedDate- 元示科技
AI Virtual Cell (AIVC): a raw biological data engine and general-purpose cell foundation model forming a life sciences base, with an ultra-high-throughput cell perturbation platform to predict drug perturbation effects across cell types, for early-stage drug discovery at pharmaceutical companies and research institutions.
Angel · 2026-10
— - HOURS
AI chemical synthesis route and process design platform plus automated experimentation, for pharma CROs/CMOs and chemical and new energy materials companies
Undisclosed · 2026-09
— - AIPher
AI-native drug discovery: proprietary drug foundation models and AI agent engine for early discovery of novel small-molecule, peptide and other drugs
Angel · 2026-09
—
Europe
BusinessLatest roundTotal raisedDate- Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M - Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M - Rivercell
In-house automated wet lab generating large-scale single-cell perturbation data to train "AI virtual cell" models that predict human cell responses to drugs and genetic changes
Seed · 2026-10
—
Other / unspecified
BusinessLatest roundTotal raisedDate- Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty
— - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.